Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can GSK Market Breo Ellipta Dosing Advantage Without Adherence Advantage?

Executive Summary

After successful advisory panel – at least for adult asthma indication – Breo Ellipta seems headed for an expanded label, but GSK is still struggling to find some clinical differentiation from its aging twice-daily Advair.

You may also be interested in...



FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel

Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.

GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair

Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.

Beyond mRNA: FDA’s Marks Calls For Platform Agnostic Search For Better COVID Vaccines

Marks opines on what sponsors would need to do to bring a ‘better’ vaccine to market in a NEJM interview. Meanwhile, CDC releases real world data on estimated bivalent booster efficacy.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel